KALI BASALYGA: Open Payments
NPI 1871218198 · SUGARLOAF, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,568 in 143 payments from 16 companies in 2025. Trend: 2023 $3,994 · 2024 $3,578 · 2025 $2,568
Food & beverage: $2,399Education: $169
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 31 | $839 |
| ABBVIE INC. | 40 | $489 |
| UCB, Inc. | 17 | $222 |
| Lilly USA, LLC | 11 | $218 |
| Novartis Pharmaceuticals Corporation | 16 | $175 |
| Galderma Laboratories, L.P. | 10 | $139 |
| Regeneron Healthcare Solutions, Inc. | 3 | $91 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $85 |
| GENZYME CORPORATION | 2 | $59 |
Products named: TREMFYA, SKYRIZI, DUPIXENT, Bimzelx, RINVOQ, TALTZ, COSENTYX, NEMLUVIO.
Industry payments across PA — which companies pay providers there.
